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Background: Preterm birth (PTB), low birth weight (LBW) and small for gestational age (SGA) contribute to
neonatal mortality. Maternal HIV-1 infection has been associated with an increased risk of PTB, but mechanisms
underlying this association are undefined. We describe correlates and outcomes of PTB, LBW, and SGA in
HIV-exposed uninfected infants.
Methods: This was a retrospective analysis of cohort study. Between 1999–2002, pregnant, HIV-infected women
were enrolled into an HIV-1 transmission study. Logistic regression was used to identify correlates of PTB, LBW and
SGA in HIV-negative, spontaneous singleton deliveries. Associations between birth outcomes and mortality were
measured using survival analyses.
Results: In multivariable models, maternal plasma (OR = 2.1, 95% CI = 1.1-3.8) and cervical HIV-1 RNA levels (OR =
1.6, 95% CI = 1.1-2.4), and CD4 < 15% (OR = 2.4, 95% CI = 1.0-5.6) were associated with increased odds of PTB.
Abnormal vaginal discharge and cervical polymorphonuclear leukocytes were also associated with PTB. Cervical
HIV-1 RNA level (OR = 2.4, 95% CI = 1.5-6.7) was associated with an increased odds of LBW, while increasing parity
(OR = 0.46, 95% CI = 0.24-0.88) was associated with reduced odds. Higher maternal body mass index (OR = 0.75,
95% CI = 0.61-0.92) was associated with a reduced odds of SGA, while bacterial vaginosis was associated with
>3-fold increased odds (OR = 3.2, 95% CI = 1.4-7.4). PTB, LBW, and SGA were each associated with a >6-fold increased
risk of neonatal death, and a >2-fold increased rate of infant mortality within the first year.
Conclusions: Maternal plasma and cervical HIV-1 RNA load, and genital infections may be important risk factors for
PTB in HIV-exposed uninfected infants. PTB, LBW, and SGA are associated with increased neonatal and infant mortality
in HIV-exposed uninfected infants.
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Globally, it is estimated that there are more than 13 mil-
lion preterm births (PTB) annually, comprising 11% of
live births, with the highest burden in low-income coun-
tries [1,2]. PTB is both a direct and indirect leading
cause of mortality in the neonatal period, accounting for
28% of global neonatal deaths [3]. Low birth weight* Correspondence: jslyker@uw.edu
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are also at elevated risk for death (reviewed in [4]). Be-
yond the neonatal period, preterm infants are at an in-
creased risk of morbidity and mortality, developmental
delays, lower educational attainment, and increased
lifetime risk of non-communicable diseases [5].
Mechanisms resulting in PTB are not fully understood.
Maternal infection, and vaginal infection in particular, is
thought to be a major pathway to PTB [6,7]. Markers of
inflammation and infection have been associated with
PTB, and treatment for some vaginal infections has been
shown to reduce the rates of PTB [7,8]. To date, atd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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birth outcomes in the setting of maternal HIV-1 infec-
tion, with variable findings. Maternal plasma HIV-1
RNA load, CD4 counts and symptomatic disease have
been associated with PTB in some studies but not
others [9-11]. Differences in sociodemographics, behav-
ior, genetics, vaginal flora, co-infections, secular time,
and delivery inclusion/exclusion criteria (gestational age
cutoff, elective caesarean sections and twins), undoubt-
edly result in confounding, which could attenuate
observed associations with PTB.
Maternal antiretroviral therapy (ART) for either pre-
vention of mother to child transmission (PMTCT) or
treatment has introduced further complexity to discern-
ing relationships between HIV-1 and birth outcomes.
The risk of PTB declined in HIV-infected women during
the period between 1989–2004 in the United States [12],
in contrast to increasing rates of PTB in the general
population during the same period [13], suggesting that
virologic suppression and/or immune reconstitution
likely improves birth outcomes on the whole. However,
some studies have shown differences in PTB rates by
maternal ART regimen, protease-inhibitor use, or timing
of ART initiation, suggesting specific drugs, or drug
classes may increase the risk of PTB [14,15]. Current
evidence suggests the use of protease-inhibitor (PI)-
based regimens may increase the risk of PTB over that
of non-PI-based regimens [16,17].
As ART use expands in sub-Saharan Africa, the popu-
lation of HIV-1 exposed uninfected infants continues to
grow. HIV-exposed uninfected infants have increased
rates of morbidity and mortality compared to unexposed
infants (reviewed in [18]). The reason for increased mor-
bidity among HIV-exposed uninfected infants is likely
due to a combination of factors including reduced
maternal transfer of antibodies, increased exposure to
infectious pathogens from their mother, and altered im-
munologic development. Studies to better understand
the vulnerability of HIV-exposed uninfected children will
enable the development of strategic interventions to
optimize outcomes in this unique population. Utilizing
data from an historic perinatal cohort, we estimated the
incidence of PTB, LBW, and SGA in a cohort of
HIV-infected women and their uninfected infants. We
additionally determined correlates of PTB, LBW and
SGA; and quantified their association with infant morta-
lity during the first year of life.
Methods
Study population
Protocols were approved by the Institutional Review
Board of the University of Washington and the Ethics
and Research Committee of Kenyatta National Hospital.
HIV-infected women with gestation ≥28 weeks wererecruited from Nairobi antenatal clinics from 1999-
2002 [19]. Fetal gestation at enrollment was estimated
by a combination of last menstrual period and fundal
height. Women received short-course zidovudine for
PMTCT [19].Clinical assessments and follow-up
Medical and obstetric histories were recorded at enroll-
ment. At 32 weeks, clinicians performed a pelvic exam-
ination and collected blood and genital specimens
for sexually transmitted infection (STI) screening [20].
Trichomonas vaginalis was diagnosed from vaginal
swabs by in-pouch culture testing using the APTIMA
platform (Gen-Probe, San Diego, California). Cervical
swabs were used for Neisseria gonorrhoeae and Chla-
mydia trachomatis testing using the Amplicor CT/NG
test (Roche Molecular Systems Inc, Branchburg, New
Jersey). Treponema pallidum was diagnosed by the
rapid plasma reagin test (Becton and Dickinson, Franklin
Lakes, New Jersey) with confirmation by Treponema
pallidum haemagglutination assay (Randox Laboratories
Ltd, Crumlin, UK). Bacterial vaginosis (BV) was diag-
nosed using Nugent criteria from Gram-stained vaginal
smears and Candida was identified by visualization of
vaginal wet mount. Sexually transmitted and vaginal in-
fections were treated as indicated. Mothers returned
monthly for interviews and clinical assessments.
Neonates were examined at birth by a study physician.
For deliveries outside the study site, birth weight data
was abstracted from facility records or government-
issued mother-child health booklets. Infant gestational
age at birth was assessed via Dubowitz scoring [21]. In
the absence of Dubowitz, last menstrual period was
used to estimate gestational age for overall incidence
estimates. Mother-infant pairs attended monthly visits
in the clinic for one year. For deceased infants, age at
death was determined by a physician following a
chart review and/or verbal autopsy with the parent or
guardian [19,22].Definitions
Infants were considered preterm births (PTB) if born be-
fore 37 weeks. Low birth-weight (LBW) was defined as
less than 2.5 kg. To account for early neonatal weight
loss, weight data were only included from infants
weighed within 24 hours of birth. Similarly, analysis of
Dubowitz assessments was restricted to those conducted
within 3 days of birth. Small for gestational age (SGA)
was determined via the method outlined by Mikolajczyk
[23] utilizing the mean birth weight at 40 weeks in our
cohort and the standard deviation specific to our
sample, and using Dubowitz-estimated gestational age.
Neonatal and infant mortality were defined as deaths
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respectively.
HIV-1 testing and viral loads
HIV-1 RNA loads were measured using the GenProbe
assay [24] in plasma and cervical swabs at 32 weeks, and
in maternal plasma at delivery. HIV-1 testing was per-
formed on infant blood at birth (<48 hours) and 1, 3, 6,
9 and 12 months. Infant HIV-1 infection was defined by
the detection of HIV-1 DNA in dried blood spots [25] or
RNA in plasma [24]. Uninfected infants received a
confirmatory HIV-1 ELISA at study exit.
Statistical methods
Stata SE v11.2 for Macintosh (StataCorp, College Station,
Texas) was used for all analyses. All tests were two-tailed
with alpha = 0.05. Overall estimates of PTB rates included
deliveries where either Dubowitz or last menstrual period
was available. Fisher’s exact test was used to compare the
proportion of PTBs between infants with and without
HIV-1 detection at birth.
Analyses for correlates of adverse birth outcomes and
mortality were limited to spontaneous deliveries of
singleton, HIV-uninfected infants. We excluded twins
(n = 7 sets), planned cesarean sections (n = 20), infants
who were HIV-infected at birth (n = 29), and those who
lacked an HIV-1 test at birth (1 intrapartum death and 7
stillbirths). When analyzing correlates of PTB, we used
only infants with Dubowitz assessment, because this
method is more reliable than last menstrual period when
compared to ultrasound [26].
Logistic regression was used to identify correlates of
PTB, LBW and SGA. Covariates included a priori
defined variables based on literature review and hypoth-
esized relationships between maternal HIV-1 and birth
outcome. In order to generate meaningful estimates, we
required a minimum of 10 exposures for each covariate
included in regression models; for this reason several well-
defined risk factors (smoking, pre-eclampsia, eclampsia,
Neisseria gonorrhoeae) were not evaluated because they
were uncommon in this cohort (numbers are provided in
Table 1). We used stepwise logistic regression to create final
multivariable models; for each of the three outcomes we
included all covariates with p values ≤0.1, then performed
backward elimination of covariates until we had a best-fit
model. Pearson’s correlation was used to measure the cor-
relation between plasma and cervical HIV-1 RNA loads;
these terms were collinear so they were not included to-
gether in any multivariable models and we present alterna-
tive models including each separately. Similarly, we made
separate models for either viral load or CD4 because these
terms were also collinear. In multivariable analyses, we
elected to adjust for CD4 percent as an indicator of im-
munosuppression, rather than CD4 count, because CD4percent is not affected by increasing blood volume during
pregnancy, which causes a decline in CD4 cells/mm3.
Mortality rates are reported separately for the neonatal
(28 day) and infant (365 day) periods. All spontaneously-
delivered infants born HIV-negative were considered at
risk from birth; we excluded from this analysis infants
who acquired HIV-1 later during follow-up. Kaplan-
Meier survival analysis was used to estimate the neonatal
mortality incidence rate; surviving children were cen-
sored at 28 days. For infant mortality, individuals were
censored at study exit, or 1 year, whichever came first.
Cox proportional hazards regression was used to esti-
mate hazard ratios (HR) for PTB, LBW, and SGA, indi-
vidually, and adjusted for maternal plasma HIV-1 RNA
load at 32 weeks gestation, with censoring at study exit
or 1 year, whichever came first. Kaplan-Meier survival
plots with the log-rank statistic are provided to illustrate
differences between mortality in the different groups
over time.
Results
Overall rate of preterm birth
A total of 475 women delivered 482 infants. Gestational
age was estimated using Dubowitz (385 women) or last
menstrual period (80 women) in 465 women. The over-
all PTB rate was 14% (65/465). PTB comprised 28%
(8/29) of deliveries of HIV-infected infants (inclusive of
2 twin deliveries), and 13% (57/429) of HIV-uninfected
infants (inclusive of 5 twin deliveries, p = 0.05).
Participant characteristics
A total of 413 women spontaneously delivered live,
singleton infants who were HIV-negative at birth
(Figure 1); 332 infants (80%) had weight assessed
within the first day, 335 (81%) had Dubowitz assessed
within 3 days, and 311 (75%) had both Dubowitz and
weight assessed within the specified time limits
enabling calculation of SGA. Of the 413 infants born
HIV-negative, 54 (13%) later acquired HIV-1.
Characteristics of the women who spontaneously de-
livered live, singleton HIV-negative infants are detailed
in Table 1. Most mothers were young and married. The
majority of deliveries occurred at the study site, Kenyatta
National Hospital (85%). Cigarette smoking alcohol use,
pre-eclampsia and eclampsia were rare. Vaginal infec-
tions were common; 37% of women had BV, 30% had
Candida, and 21% had a laboratory-confirmed STI at
32 weeks gestation.
Rates of PTB, LBW and SGA in spontaneously delivered,
singleton, HIV-uninfected infants
There were 33 spontaneous, singleton preterm deliveries of
HIV-exposed uninfected infants (9.9%). The median gesta-
tional age of PTB infants was 35 weeks, (IQR = 34-36).
Table 1 Population characteristics of HIV-infected
women spontaneously delivering singleton,
HIV-uninfected infants
N Median (IQR) or
proportion (n)
Sociodemographic
Married 413 90% (372)
Employed 413 30% (123)
Years education 408 8 (8–11)
Physical and Obstetric (Current
pregnancy)
Age (years) 413 25 (22–28)
Body mass index at 32 weeks 400 24 (23–26)
Parity 409 1 (1–2)
Pre-eclampsia 408 1.5% (6)
Eclampsia 407 0.25% (1)
Place of delivery
Kenyatta National Hospital 412 85% (350)
Other facility 412 6.1% (25)
Home 412 7.5% (31)
En route to hospital 412 1.5% (6)
Caesarean section 394 15% (58)
Alcohol use 410 3.9% (16)
Cigarette smoking 412 1.2% (5)
Vaginal infections at 32 weeks
Bacterial vaginosis 385 37% (144)
Candida 408 30% (124)
Cervical PMN ≥3 per high-powered
field
336 61% (204)
Abnormal vaginal discharge 408 50% (204)
Cervical blood 408 4.7% (19)
Trichomonas vaginalis 408 16% (65)
Chlamydia trachomatis 407 3.9% (16)
Treponema pallidum 409 2.4% (10)
Neisseria gonorrhoeae 407 2.0% (8)
Any sexually transmitted infectiona 413 21% (88)
Immunologic and virologic
CD4 cells/mm3 <350 401 34% (137)
CD4 percent <15 401 15% (60)
Log10 plasma HIV-1 RNA load 396 4.7 (4.2-5.2)
Log10 cervical HIV-1 RNA load 315 2.0 (1.4-2.9)
Cervical HIV DNA detectable 315 72% (227)
Delivery
Baby female 412 46% (191)
Dubowitz estimated maturity
(weeks)
335 40 (39–41)
Premature 335 9.9% (33)
33 35 (34–36)
Table 1 Population characteristics of HIV-infected
women spontaneously delivering singleton,
HIV-uninfected infants (Continued)
Dubowitz estimated maturity in
preterm (weeks)
Low birth weight 332 6.0% (20)
Birth weight in low birth weight
infants (kg)
332 2.2 (1.5-2.4)
Small for gestational age 311 9.0% (28)
Notes. All clinical assessments and laboratory measurements were performed
at 32 weeks gestation. aIncludes laboratory-confirmed Neisseria gonorrhoeae,
Trichomonas vaginalis, Chlamydia trachomatis, and Treponema pallidum.
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within 24 hours, 11 (38%) were also LBW and 3 were
SGA (10%). A total of 6.0% (20/332) of infants were
LBW. A large proportion of LBW cases were explained
by preterm delivery, 61% (11/18). Overall, 9.0% of in-
fants were SGA (28/311); 11% of these SGA infants had
been born preterm.
Correlates of PTB, LBW and SGA among spontaneous,
singleton HIV-negative deliveries
Maternal cervical HIV-1 RNA load (odds ratio (OR) =
1.8, p = 0.001), plasma HIV-1 RNA load (OR = 1.9, p =
0.02), and CD4 percent < 15 (OR = 3.3, p = 0.004) were
associated with an increased odds of PTB (Table 2). No
specific STIs or genital infections were significantly asso-
ciated with PTB. However, abnormal vaginal discharge
(OR = 2.4, p = 0.03), detection of cervical polymorpho-
nuclear leukocytes (PMN) at a density of ≥3 per high-
power field (the cohort median; OR = 3.2, p = 0.02), and
detection of blood in the cervix (OR = 5.1, p = 0.002)
were associated with an increased odds of PTB. There
was a non-significant increased odds of PTB in women
with BV diagnosed at 32 weeks (OR = 2.1, p = 0.06).
Correlates of LBW included cervical HIV-1 replication
at 32 weeks gestation; each 1-log increase in cervical
HIV-1 RNA load was associated with a >2-fold increased
odds of LBW (OR = 2.1, p < 0.001). Higher maternal
body mass index (BMI, OR = 0.74, p = 0.004) at 32 weeks
gestation and increasing parity (OR = 0.52, p = 0.02) were
associated with reduced odds of LBW.
Unlike PTB and LBW, no maternal immune or viro-
logic indicators were significantly associated with SGA.
SGA was more common in female infants (OR = 2.7, p =
0.02), and in the presence of maternal BV (OR = 3.2, p =
0.005). Higher BMI at 32 weeks gestation was associated
with reduced odds of SGA (OR = 0.80, p = 0.007).
Adjusted correlates of PTB, LBW and SGA among
spontaneous, singleton HIV-negative deliveries
The odds of PTB were independently associated with
cervical PMN detection (OR = 2.9, 95% CI = 1.2-7.3; p =
510 enrolled
475 deliveries
35 lost before delivery
468 singleton infants
7 sets of twins
460 live singleton births 
with HIV-1 testing
8 infants with no HIV-1 test
(7 still births, 1 intrapartum death)
440 spontaneous births
20 planned caesarean section deliveries
413 infants HIV-negative 
at birtha
27 infants HIV-infected at birth
332 have weight
assessed < 1 day of birth
335 have Dubowitz
assessed < 3 days of birth
311 have SGA calculated
(weight & Dubowitz assessed < 1 day of birth)
Figure 1 Patient flow chart.
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95% CI = 1.2-7.9; p = 0.02; Model 1), log10 plasma HIV-1
RNA load (OR = 2.1, 95% CI = 1.1-3.8; p = 0.03; Model
1), log10 cervical HIV-1 RNA load (OR = 1.6, 95% CI =
1.1-2.4; p = 0.02; Model 2), and CD4% less than 15%
(OR = 2.4, 95% CI = 1.0-5.6; p = 0.05; Model 3). The odds
of LBW (Model 4) were independently associated with
log10 plasma HIV-1 RNA load (OR = 2.4, 95% CI = 1.5-
6.7; p < 0.001), whereas each additional live birth in a
woman’s history was associated with reduced odds of
LBW (OR for parity = 0.46, 95% CI = 0.24-0.88; p = 0.02).
BV was associated with a >3-fold increased odds of SGA
(Model 5; OR = 3.2, 95% CI = 1.4-7.4; p = 0.007), whereas
each 1-unit increase in maternal BMI at 32 weeks gesta-
tion was associated with a 25% reduced odds of SGA
(OR = 0.75, 95% CI = 0.61-0.92; p = 0.005).
PTB, LBW, SGA and mortality
From the subset of 413 infants born HIV-negative, 359
remained HIV-uninfected until study exit or death;
of these 287 had Dubowitz assessed within 72 hours of
birth, 287 had birth weight assessed within 24 hours of
birth, and 268 had SGA evaluated (both Dubowitz and
birth weight assessed in 48 hours).
A total of 32 infant deaths were recorded in the HIV-
exposed uninfected infants during the first year of life,
and 13 occurred during the first 28 days of life. The neo-
natal mortality incidence rate (IR) for infants born PTB
was 7-fold higher than infants born at term (IR = 5.8 vs
0.81 per 1000 person-days, incidence rate ratio (IRR) =
7.1, 95% CI = 1.5-30, p = 0.008). The neonatal mortality
IR for infants born LBW was more than 6-fold higher
than infants born at normal weight (IR = 6.7 versus 1.0
per 1000 person-days, IRR = 6.4, 95% CI = 1.1-27, p =
0.02). The neonatal mortality IR for infants born SGAwas 7-fold higher than infants born with normal weight
for gestational age (5.4 versus 0.73 per 1000 person-
days, IRR = 7.4, 95% CI = 1.5-34, p = 0.009).
We also examined associations between PTB, LBW
and SGA and infant survival during the first year of life.
In unadjusted analyses, PTB, LBW, SGA, and maternal
prenatal HIV-1 RNA load were all associated with an in-
creased rate of infant death (Table 3 & Figure 2). When
adjusting for maternal plasma HIV-1 RNA load at 32
weeks gestation, PTB (hazard ratio (HR) = 2.7, p = 0.05),
LBW (HR = 3.3, p = 0.03) and SGA (HR = 2.9, p = 0.04)
remained independently associated with time to infant
death.
Discussion
This study identified several potentially modifiable fac-
tors that were associated with PTB, LBW, and SGA
among HIV-exposed uninfected infants. Maternal genital
infection was a predominant correlate of PTB in this co-
hort: cervical HIV-1 RNA load, the detection of PMN in
cervical fluid, and vaginal discharge were all associated
with increased odds of PTB. Cervical HIV-1 RNA load
was also independently associated with an increased
likelihood of delivering a LBW infant. BV and maternal
BMI in pregnancy were independently associated with
SGA, but HIV-1 RNA load was not. The consequences
of being born preterm or small were profound; PTB,
LBW and SGA were each significantly associated
with >6-fold increased neonatal mortality rate and a >2-
fold increased infant mortality rate. These data demon-
strate that PTB, LBW, and SGA may be associated with
mortality in HIV-exposed uninfected children, and sug-
gest that reduction of maternal genital HIV-1 replication
could be a strategy to reduce the risk of late preterm
birth and low birth weight deliveries.
Genital infection/inflammation, as indicated by vaginal
discharge and PMN in cervical swabs, emerged as im-
portant predictors of PTB and LBW in this cohort. To
our knowledge, this is the first report demonstrating an
association between HIV-1 RNA load in cervical fluid
and PTB or LBW. Ascending infection into the uterus is
one mechanism by which lower genital infections are
thought to trigger PTB [27]. Additionally, the process of
cervical ripening could be accelerated by HIV-induced
inflammation and migration of leukocytes to infected
cervical tissue. Cervicitis has been associated with PTB
and/or LBW delivery in several studies [28,29], and a
study by Brown and colleagues reported an association
between the detection of cervical HSV-2 shedding and
PTB [30]. Together, these data are consistent with the
evolving model of PTB that includes maternal genital in-
fection as a primary pathway leading to PTB (discussed
in [27,31]). Whether any of these associations are causal
in nature is beyond the scope of our study, however, they
Table 2 Correlates of prematurity, low birth weight and small for gestational age deliveries of HIV-exposed uninfected infants
Preterm Low birth weight Small for gestational age
A) Univariable analysis OR [95% CI] P OR [95% CI] P OR [95% CI] P
Female infant 1.1 [0.53-2.3] 0.8 2.3 [0.88-5.8] 0.09 2.7 [1.2-6.2] 0.02
Married 1.8 [0.42-8.0] 0.4 0.65 [0.18-2.3] 0.5 0.88 [0.25-3.1] 0.8
Employed 0.87 [0.39-1.9] 0.7 1.0 [0.39-2.8] 0.9 1.0 [0.42-2.4] >0.9
Years education 0.89 [0.78-1.0] 0.1 1.1 [0.94-1.3] 0.2 1.1 [0.96-1.3] 0.1
Age (years) 0.97 [0.89-1.1] 0.5 0.93 [0.83-1.0] 0.2 0.97 [0.89-1.1] 0.5
Body mass index 0.90 [0.78-1.0] 0.1 0.74 [0.61-0.91] 0.004 0.80 [0.68-0.94] 0.007
Parity 0.91 [0.68-1.2] 0.6 0.52 [0.30-0.89] 0.02 0.78 [0.53-1.1] 0.2
Alcohol use b c 1.7 [0.37-8.2] 0.5
Bacterial vaginosis 2.1 [0.97-4.4] 0.06 2.1 [0.78-5.6] 0.1 3.2 [1.4-7.3] 0.005
Candida 0.90 [0.40-2.0] 0.8 1.1 [0.41-3.1] 0.8 0.74 [0.30-1.8] 0.5
Cervical PMN ≥3 per high-powered fielda 3.2 [1.2-8.9] 0.02 2.9 [0.81-10] 0.1 1.9 [0.75-4.7] 0.2
Abnormal vaginal discharge 2.4 [1.1-5.2] 0.03 1.8 [0.70-4.7] 0.2 0.89 [0.41-1.9] 0.8
Cervical blood 5.1 [1.8-14] 0.002 2.5 [0.52-12] 0.3 0.65 [0.083-5.1] 0.7
Trichomonas vaginalis 0.64 [0.19-2.2] 0.5 0.32 [0.042-2.5] 0.3 0.72 [0.21-2.5] 0.6
Chlamydia trachomatis 1.7 [0.35-7.8] 0.5 3.4 [0.69-17] 0.1 0.82 [0.10-6.6] 0.9
Treponema pallidum b 1.8 [0.21-15] 0.6 1.1 [0.14-9.2] 0.9
Any sexually transmitted infection 0.68 [0.25-1.8] 0.4 0.91 [0.30-2.8] 0.9 0.81 [0.29-2.2] 0.7
CD4 cells/mm3 <350 1.9 [0.90-4.0] 0.09 2.0 [0.79-5.3] 0.1 1.1 [0.50-2.5] 0.8
CD4 percent <15 3.3 [1.4-7.7] 0.004 1.8 [0.58-5.9] 0.3 1.0 [0.33-3.1] >0.9
Log10 HIV plasma HIV-1 RNA load at 32 weeks 1.9 [1.1-3.1] 0.02 1.5 [0.81-2.9] 0.2 1.1 [0.69-1.8] 0.7
Log10 HIV cervical HIV-1 RNA load at 32 weeks 1.8 [1.3-2.5] 0.001 2.1 [1.4-3.2] <0.001 1.3 [0.88-1.8] 0.2
Preterm Low birth weight Small for gestational age
B) Multivariable analyses OR [95% CI] P OR [95% CI] P OR [95% CI] P
Model 1 (includes plasma HIV-1 RNA load)
Cervical PMN ≥3 per high-powered field 2.9 [1.2-7.3] 0.02 * *
Abnormal vaginal discharge 3.1 [1.2-7.9] 0.02 * *
Log10 HIV plasma HIV-1 RNA load 2.1 [1.1-3.8] 0.03 * *
Model 2 (includes cervical HIV-1 RNA load)
Cervical PMN ≥3 per high-powered field 2.7 [1.0-7.3] 0.05 * *
Abnormal vaginal discharge 3.6 [1.2-10] 0.02 * *
Log10 HIV cervical HIV-1 RNA load 1.6 [1.1-2.4] 0.02 * *
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Table 2 Correlates of prematurity, low birth weight and small for gestational age deliveries of HIV-exposed uninfected infants (Continued)
Model 3 (includes CD4 percent <15)d
Cervical PMN ≥3 per high-powered field 3.5 [1.4-8.6] 0.007 * *
Abnormal vaginal discharge 3.2 [1.3-8.2] 0.01 * *
CD4 percent <15 2.4 [1.0-5.6] 0.05 * *
Model 4
Parity * 0.46 [0.24-0.88] 0.02 *
Log10 HIV cervical HIV-1 RNA load * 2.4 [1.5-6.7] <0.001 *
Model 5
Body mass index * * 0.75 [0.61-0.92] 0.005
Bacterial vaginosis * * 3.2 [1.4-7.4] 0.007
Notes. All clinical assessments and laboratory measurements were performed at 32 weeks gestation. aCohort median for polymorphonuclear cells (PMN) detected was 3. bNo women who used alcohol during
pregnancy, and no women with Treponema pallidum delivered preterm. cNo women who used alcohol during pregnancy delivered a low birth weight infant. B) Multivariable logistic regression models. Stepwise
logistic regression was used to create final multivariable models for each of the three outcomes as described in the Statistical Methods; because plasma HIV viral load, cervical HIV viral load, and CD4 percent were
collinear, we adjusted for these in separate models. dAn alternative model including CD4 < 350 cells/mm3 returned point estimates for PMN and vaginal discharge that were similar to Model 3 (data not shown). *
indicates that this outcome was not assessed in the model.
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Table 3 Correlates of infant mortality during 12-month follow-up
Unadjusted Adjusted for maternal plasma HIV-1 RNA load
N HR [95% CI] P value N aHR [95% CI] P value
Preterm birth 287 3.9 [1.5-10] 0.004 275 2.7 [1.0-7.5]b 0.05
Low birth weight 287 4.5 [1.7-12] 0.003 277 3.3 [1.1-10]c 0.03
Small for gestational age 268 3.0 [1.1-8.1] 0.03 258 2.9 [1.0-8.0]d 0.04
Maternal log10 HIV plasma HIV-1 RNA load
a 342 1.8 [1.1-2.9] 0.03 b, c, d
Notes. Includes only children remaining HIV-uninfected throughout follow-up. Cox regression, censored at 1 year. Each outcome was adjusted separately for
maternal log10 plasma HIV-1 RNA load.
aViral load measured at 32 weeks gestation. baHR = 1.6, p = 0.2 for HIV-1 RNA load. caHR = 1.2, p = 0.5 for HIV-1 RNA load.
daHR = 1.4, p = 0.3 for HIV-1 RNA load.
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http://www.biomedcentral.com/1471-2393/14/7point toward reduction of cervical infection or inflam-
mation as potential interventions to reduce the risk of
PTB.
The overall rate of PTB (14%) in this cohort of HIV-
infected women was similar to general population
estimates for Kenya in 2010 (10-15% [1]). Although
HIV-infected women have been shown to be at an in-
creased risk of PTB in research studies, population rates
of PTB in HIV-infected women may be counterbalanced
by their overall reduced fertility and increased mortality.
Additionally, because women were enrolled after 28
weeks, extremely preterm deliveries were not measured,
which could explain the low rate of PTB observed in this
cohort. Consistent with previous studies, we found a
higher rate of PTB in infants born HIV-infected com-
pared to those born HIV-uninfected [12,32]. Maternal
HIV-1 RNA load, CD4 count, and/or advanced HIV-1
disease have been associated with PTB in previous
studies [10,11]. Similarly, we observed independent asso-
ciations between maternal plasma HIV-1 RNA load, im-
munosuppression and PTB. Because plasma HIV-1 RNA
load, cervical HIV-1 RNA load, and immunosuppression
are strongly correlated with one another, is difficult to
determine the potential contribution of each to PTB.
LBW deliveries were associated with maternal weight,
BMI, and parity, consistent with previous reports in both
HIV-infected and uninfected populations [33,34]. In a
study of HIV-infected women from Mombasa, Kenya
correlates of LBW included age, education, primiparity,0.00
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[35]. Maternal HIV-1 RNA load and/or CD4 count have
also been associated with LBW, intrauterine growth re-
striction, or SGA [9,11,34]. In our multivariable analyses,
only parity and cervical HIV-1 RNA load were inde-
pendently associated with LBW. The association be-
tween LBW and cervical HIV-1 RNA load could be
explained by the large degree of overlap between PTB
and LBW infants; this is somewhat supported by the ob-
servation that SGA was not associated with any maternal
virologic indicators. SGA was associated with delivery of
a female infant, BMI, and BV, which is consistent with
previous studies in HIV-negative women [36,37].
Globally, PTBs account for the majority of deaths in
the neonatal period [3]. A recent meta-analysis of studies
in East Africa reported high odds ratios for death before
28 days for PTB (OR = 6.2), moderate LBW (OR = 6.2),
and SGA (2.1) compared to normal infants [38]. Simi-
larly, neonatal mortality rates were at least 6-fold higher
for PTB, LBW, and SGA infants in our study. Among
HIV-exposed uninfected infants who escaped postnatal
infection, PTB, LBW, and SGA delivery were also associ-
ated with an increased risk of infant mortality during the
first year of life. Causes of death in the HIV-exposed
uninfected infants from this cohort have been detailed
elsewhere [22]; most commonly involved were sepsis,
pneumonia and failure to thrive.
Our study has many strengths and some limitations.
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http://www.biomedcentral.com/1471-2393/14/7assessed. Most deliveries occurred at a facility, and
Dubowitz assessments of gestational age were conducted
by physicians. Since the goal of our study was to identify
modifiable maternal factors that could be targeted to re-
duce the risk of PTB and LBW deliveries, we limited
analyses to spontaneous, singleton deliveries of HIV-
uninfected infants, to reduce confounding and increase
sensitivity to detect virologic associations. Additionally,
we only included infants with Dubowitz assessment to
reduce misclassification of outcome. Although these data
are a decade old, this cohort was accrued during a time
when antiretroviral treatment was only rarely available
in Kenya; we were therefore able to look at correlates of
birth outcomes in a setting unconfounded by combin-
ation maternal antiretroviral therapy. Sociodemographic
homogeneity of the cohort, and the rarity of well-
defined risk factors such as smoking, drinking and illicit-
drug use also reduced confounding and increased our
sensitivity to detect virologic associations with birth out-
comes. However, ultrasound dating was not available,
limiting precision of gestational age estimates. Finally,
current Option B and B-plus [39] PMTCT regimens
involve maternal combination ART which may result in
different PTB estimates and correlates than we observed
in our setting of short-course zidovudine. As Option
B-plus expands treatment to a larger population of
women, it will be important to understand the effect of
maternal HAART, and different HAART regimens, on
the risk of adverse birth outcomes.
Conclusions
Our data support the association between maternal geni-
tal infection and preterm delivery in HIV-exposed un-
infected infants. As the risks and benefits of increasingly
efficacious PMTCT regimens and earlier PMTCT initi-
ation are weighed, our data suggest that reduction of
cervical viral replication could potentially reduce the risk
of PTB and LBW deliveries. Additionally, HIV-exposed
uninfected infants born PTB, LBW, or SGA are at an
elevated risk for death during the neonatal and infant
periods, and warrant heightened clinical monitoring.
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